News | Heart Valve Technology
A large observational registry found that initial aortic valve replacement (AVR) in asymptomatic patients with severe aortic stenosis (AS) was associated with a lower risk of mortality and heart failure hospitalization compared with a conservative treatment strategy.
October 27, 2015
News | Stents Drug Eluting
Results from the multicenter, prospective, randomized PANDA III trial indicate that the BuMA sirolimus-eluting stent (SES) was non-inferior to the Excel SES for the primary endpoint of target lesion failure at one year. The trial specifically examined whether the rate of drug elution and polymer absorption affects the clinical outcomes of two bioresorbable polymer-based drug-eluting stents (DES).
October 27, 2015
News | Stents Drug Eluting
OrbusNeich announced the presentation of the one-year clinical outcomes from the 1,000-patient REMEDEE Registry at the 2015 Transcatheter Cardiovascular Therapeutics (TCT) meeting, Oct. 11-15 in San Francisco. Data was presented by Robbert de Winter, M.D., Ph.D., of the Academic Medical Center, Amsterdam and principal investigator of the study.
October 26, 2015Sponsored Content
Feature | Information Technology
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
March 21, 2024
News | Stents
Medinol announced in September the completion of enrollment in its BIONICS trial to evaluate the safety and effectiveness of a new coronary stent system, the first-ever elastomeric drug eluting stent (eDES).
October 26, 2015
News | Heart Failure
CardioKinetix Inc. announced that it has received regulatory approval for the Parachute system in South Korea by the Korean Ministry of Food and Drug Safety (MFDS).
October 23, 2015
News | Stents Drug Eluting
Results of the TUXEDO trial, designed to compare two types of stents in diabetic patients, found paclitaxel-eluting stents failed to meet non-inferiority criterion compared to everolimus-eluting stents for the primary endpoint of target-vessel failure at one year.
October 23, 2015Sponsored Content
Feature | Cardiac Imaging
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
March 05, 2024
A randomized trial found that ranolazine did not reduce the composite rate of ischemia-driven revascularization or hospitalization in patients with a history of chronic angina who had residual unrevascularized coronary artery disease after percutaneous coronary intervention (PCI).
October 23, 2015
News | Heart Valve Technology
Medtronic plc released the first CoreValve transcatheter aortic valve replacement (TAVR) system outcomes data using CoreValve data from The Society of Thoracic Surgeons and American College of Cardiology (STS/ACC) Transcatheter Valve Therapy (TVT) Registry. The data show that everyday clinical experience from 6,160 CoreValve patients treated by a wide variety of heart team implanters replicates the excellent outcomes achieved in robust clinical trials. The primary outcomes of all-cause mortality and stroke in the STS/ACC TVT Registry were numerically similar to the findings in the CoreValve U.S. Pivotal Trial, which demonstrated statistical superiority to surgical aortic valve replacement in high-risk patients.
October 22, 2015News | Stents
Results from the LEADERS FREE trial found that a polymer-free drug-coated stent (DCS) was superior to a bare-metal stent (BMS) in high-bleeding-risk patients treated with one month of dual antiplatelet therapy (DAPT). It was the first randomized clinical trial dedicated to this particular patient population.
October 22, 2015Sponsored Content
Blog
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
December 11, 2023
Feature | Drug-Eluting Balloons
Results from the ISAR-DESIRE 4 trial indicate that use of a scoring balloon plus a paclitaxel-coated balloon (PCB) was angiographically superior to a paclitaxel-coated balloon alone for the treatment of restenosis within limus-eluting stents.
October 22, 2015
News | Heart Valve Technology
Direct Flow Medical Inc. announced one-year outcomes from the DISCOVER post-market study that demonstrate excellent real-world results for the Direct Flow Medical Transcatheter Aortic Valve System. The data were presented last week at the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting by Federico De Marco, M.D., from the Policlinico San Donato in Milan, Italy.
October 22, 2015
Feature | Mobile Devices
For the first time, cardiopulmonary resuscitation (CPR) guidelines issued by the American Heart Association (AHA) recommend communities consider using social media and mobile app technology to alert CPR responders when someone nearby suffers sudden cardiac arrest. The new guidelines cite studies that show emerging mobile technologies can result in a “higher rate of bystander-initiated CPR.”
October 21, 2015Sponsored Content
Case Study | Hemodynamic Monitoring Systems
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
November 14, 2023
News | Contrast Media
Bracco Diagnostics Inc. announced that Lumason was approved by the Centers for Medicare and Medicaid Services (CMS) for pass-through status under the Hospital Outpatient Prospective Payment System (HOPPS). Lumason is an ultrasound contrast agent indicated for use in adults with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.
October 21, 2015
Feature | Thrombectomy Devices
A pair of studies presented at the 27th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium showed no late benefit of thrombus aspiration during percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI).
October 20, 2015
Results from the BRAVO 3 trial found that bivalirudin did not significantly reduce major bleeding rates at 48 hours or adverse events at 30 days compared to heparin in high-risk patients undergoing transcatheter aortic valve replacement (TAVR).
October 20, 2015© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now